Case Report: Clinical manifestations of uncommon monogenic disorders: revisiting activated phosphoinositide 3-kinase delta syndrome 2
Open Access
- 29 April 2025
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1570600
Abstract
Aim: Pediatricians are trained to identify recurrent or unusual infections in children, prompting evaluation for inborn errors of immunity (IEI). Some monogenic IEI, however, may present atypically. This study describes our experience with children diagnosed with activated phosphoinositide 3-kinase delta syndrome (APDS2) including unusual presentations.Methods: A retrospective review was conducted on two children diagnosed with APDS2 at Shaare Zedek and Sheba Tel-Hashomer Medical Centers in Israel. Both patients underwent immune assessments, genetic testing, and treatment between 2019 and 2024.Results: Two patients, a 17-year-old female (P1) and a 7-year-old male (P2), were diagnosed with APDS2 after presenting with recurrent juvenile parotitis (P1) and severe lymphadenopathy (P2). Immunologic evaluation revealed hypogammaglobulinemia and combined immune deficiency. Genetic testing identified PIK3R1 variants (c.1425 + 1G > T in P1 and c.1425 + 1G > C in P2). Both received intravenous immunoglobulins and prophylactic antibiotics. P2 was treated with rapamycin, leading to resolution of lymphadenopathy.Conclusion: This report highlights the clinical presentation of APDS2, a rare monogenic IEI in children, including the atypical manifestation of RJP and the common feature of lymphadenopathy. Pediatricians should stay vigilant for red flags of IEI during clinical evaluations, as early diagnosis and multidisciplinary care are crucial for effective management.Keywords
This publication has 18 references indexed in Scilit:
- Interim analysis: Open-label extension study of leniolisib for patients with APDSJournal of Allergy and Clinical Immunology, 2023
- Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunityJournal of Allergy and Clinical Immunology, 2023
- A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndromeBlood, 2023
- Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert CommitteeJournal of Clinical Immunology, 2022
- Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyJournal of Allergy and Clinical Immunology, 2017
- Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort studyJournal of Allergy and Clinical Immunology, 2016
- Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3KJournal of Experimental Medicine, 2014
- A human immunodeficiency caused by mutations in the PIK3R1 geneJournal of Clinical Investigation, 2014
- Paediatric Reference Values for the Peripheral T cell CompartmentScandinavian Journal of Immunology, 2012
- Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry.Clinical Chemistry, 1982